BPTH: חוב לטווח קצר להון עצמי Bio-Path Holdings Inc.

Bio-Path Holdings (BPTH) faces severe threats due to a high burn rate and the risk of delisting. Its scientific potential is based on the preparation of final test results for antisense drugs against leukemias. The market value dynamics of the asset, which currently stands at 0.00, complement the business profile of creating universal DNA medicines that allow for the effective adaptation of a single technology across various types of malignant tumors.

This ratio assesses the company's dependence on liabilities maturing within one year relative to its equity, where increasing values signal liquidity risk. By analyzing the trend of short-term liabilities to equity, an investor can discern the capital structure's sensitivity to interest rates, which is critical for Bio-Path Holdings (BPTH) as it finances costly DNA-based drug developments for blood cancer prior to their commercialization stage.